buyWeak
David F Hale bought $8,859 of ONCT
director at Oncternal Therapeutics, Inc.. 980 shares at an average of $9.04, traded Feb 23, 2024, filed Feb 27, 2024.
Conviction score
23Value
$8,859
980 shares
Holdings after
29,673
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- 0Trade size$9k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-24-004016, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 23, 2024 | POpen-market purchase Common Stock | +714 | $9.04 | $6,455 | 714 | Feb 27, 2024 |
| Feb 23, 2024 | POpen-market purchase Common Stockindirect: By Hale BioPharma Ventures, LLC | +266 | $9.04 | $2,405 | 29,673 | Feb 27, 2024 |
Related signals
Other insiders at Oncternal Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | ONCTbuy Oncternal Therapeutics, Inc. | Robert James Wills director | $28k 3,086 shares | +45% | |
| 30Weak | ONCTbuy Oncternal Therapeutics, Inc. | Robert James Wills director | $59k 6,914 shares | - | |
| 35Weak | ONCTsell Oncternal Therapeutics, Inc. | Robert James Wills director | $8,859 980 shares | -100% | |
| 21Weak | ONCTbuy Oncternal Therapeutics, Inc. | Gunnar F. Kaufmann Chief Scientific Officer | $9,824 28,000 shares | +42% | |
| 56Moderate | Oncternal Therapeutics, Inc. | James B Breitmeyer Chief Executive Officer | $44k 150,000 shares | +322% | |
| 36Weak | Oncternal Therapeutics, Inc. | Chase C. Leavitt General Counsel/Secretary | $7,250 25,000 shares | +31% | |
| 43Moderate | Oncternal Therapeutics, Inc. | Richard G Vincent Chief Financial Officer | $8,961 30,000 shares | +24% | |
| 33Weak | Oncternal Therapeutics, Inc. | Salim Yazji Chief Medical Officer | $7,200 25,000 shares | +18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.